Penn’s CAR-T Treatment Shrank Brain Tumors in Patients in Clinical Trial  

In a new early-stage clinical trial, a Penn-invented CAR-T treatment shrank brain tumors in seven patients with glioblastoma, a fast-growing brain cancer that can prove fatal in as little as 12-18 months following diagnosis.  Doctors delivered the CAR-T treatment to the patients by injecting genetically modified white blood cells into the spinal fluid through an intracerebral port. 
The results of the study show significant promise, despite previous challenges seen with other CAR-T treatments for solid tumors.  Researchers are continuing with this trial to determine if the treatment can reliably prevent further tumor growth for at least six months.

Read more here: 

Skip to content